Avalon Pharmaceuticals to Present at BIO CEO & Investor Conference 2007

GERMANTOWN, Md., Feb. 8  /PRNewswire-FirstCall/ -- Avalon Pharmaceuticals, Inc. (Nasdaq and NYSE Arca: AVRX), today announced that Kenneth C. Carter, Ph.D., President and CEO and Michael Hamilton, M.D., Chief Medical Officer will be presenting and participating at the BIO CEO & Investor Conference 2007. The meeting will be held at the Waldorf-Astoria Hotel in New York City from February 12-14.

Dr. Carter is scheduled to provide an update on the company on Tuesday, February 13, at 11:15 a.m. EST in the Morgan Room.  A live audio webcast of this presentation can be accessed on Avalon Pharmaceuticals' website, http://www.avalonrx.com/ and a replay of the presentation will be available for 90 days following the conference.

Dr. Hamilton is scheduled to participate in the therapeutics workshop entitled, "Blood-borne Cancers - The Alphabet Soup of Leukemia" on Monday, February 12 at 3:30 p.m. EST in the Jade Room.

About Avalon Pharmaceuticals

Avalon Pharmaceuticals is a biopharmaceutical company using its proprietary technology, AvalonRx(R), to discover and develop cancer therapeutics.  Avalon has a lead product in Phase I clinical development (AVN944 -IMPDH inhibitor), preclinical programs to discovery inhibitors for the beta-catenin and aurora pathways and value generating partnerships with MedImmune, Medarex, and Novartis. Avalon Pharmaceuticals was established in 1999 and is headquartered in Germantown, Md.

About AvalonRx(R)

AvalonRx(R) is a comprehensive, innovative and proprietary suite of technologies based upon large-scale gene expression analysis. This platform facilitates drug discovery by expanding the range of therapeutic targets for drug intervention, including targets and target pathways frequently considered intractable using conventional HTS approaches. It allows more informed decisions about which compounds to advance towards clinical trials, and facilitates drug development through identification of biomarkers of efficacy that can stratify patients or provide early indicators of response.

  Contacts:
  Avalon Pharmaceuticals, Inc.
  Gary Lessing
  Executive Vice President & CFO
  Tel: [phone]
  Fax: [phone]
  Email: 

  Noonan Russo
  Wendy Lau (Media)
  Tel: [phone]

  The Trout Group LLC
  Chad Rubin (Investors)
  Tel: [phone] ext. 47


DATASOURCE: Avalon Pharmaceuticals, Inc.



CONTACT:  Gary Lessing, Executive Vice President & CFO, Avalon

Pharmaceuticals, Inc., [phone], Fax: [phone],

; or Media: Wendy Lau, Noonan Russo, [phone]; or

Investors: Chad Rubin, The Trout Group LLC, [phone] ext. 47



Web site:  http://www.avalonrx.com/ 

Copyright